JP2004507712A - アルツハイマー病のマーカーとしてのニューロステロイド - Google Patents

アルツハイマー病のマーカーとしてのニューロステロイド Download PDF

Info

Publication number
JP2004507712A
JP2004507712A JP2001555784A JP2001555784A JP2004507712A JP 2004507712 A JP2004507712 A JP 2004507712A JP 2001555784 A JP2001555784 A JP 2001555784A JP 2001555784 A JP2001555784 A JP 2001555784A JP 2004507712 A JP2004507712 A JP 2004507712A
Authority
JP
Japan
Prior art keywords
dhea
disease
cells
levels
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001555784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507712A5 (https=
Inventor
パパドポーロス、バッシリオス
ブラウン、ラチェル、シー
カシオ、カテリーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of JP2004507712A publication Critical patent/JP2004507712A/ja
Publication of JP2004507712A5 publication Critical patent/JP2004507712A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
JP2001555784A 2000-01-28 2001-01-26 アルツハイマー病のマーカーとしてのニューロステロイド Pending JP2004507712A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17869800P 2000-01-28 2000-01-28
PCT/US2001/002476 WO2001055692A2 (en) 2000-01-28 2001-01-26 Neurosteroids as markers for alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2004507712A true JP2004507712A (ja) 2004-03-11
JP2004507712A5 JP2004507712A5 (https=) 2008-03-21

Family

ID=22653575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001555784A Pending JP2004507712A (ja) 2000-01-28 2001-01-26 アルツハイマー病のマーカーとしてのニューロステロイド

Country Status (8)

Country Link
EP (1) EP1254251B1 (https=)
JP (1) JP2004507712A (https=)
AT (1) ATE370416T1 (https=)
AU (2) AU785364B2 (https=)
CA (1) CA2398358A1 (https=)
DE (1) DE60129932T2 (https=)
ES (1) ES2290111T3 (https=)
WO (1) WO2001055692A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100092A2 (en) * 2002-05-28 2003-12-04 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
FR2847038B1 (fr) * 2002-11-07 2005-01-07 Conservatoire Nat Arts Procede de diagnostic de maladies neurodegeneratives
US7576073B2 (en) 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
CN102998464A (zh) * 2011-09-16 2013-03-27 武汉优尔生科技股份有限公司 脱氢表雄酮酶联免疫吸附测定试剂盒的研制方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053315A1 (en) * 1997-05-19 1998-11-26 Bayer Corporation Immunoassays using anti-allotypic monoclonal antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053315A1 (en) * 1997-05-19 1998-11-26 Bayer Corporation Immunoassays using anti-allotypic monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010026054, Ｃ．Ｃａｓｃｉｏ ｅｔ ａｌ．, "Ｄｅｔｅｃｔｉｏｎ ｏｆ Ｐ４５０ｃ１７−ｉｎｄｅｐｅｎｄｅｎｔ ｐａｔｈｗａｙｓ ｆｏｒ ｄｅｈｙｄｒｏｅｐｉａｎｄｒｏｓｔｅｒｏｎｅ（ＤＨＥＡ） ｂｉｏｓｙｎｔｈｅｓｉｓ ｉｎ ｂｒａｉｎ ｇｌｉ", Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ． ＵＳＡ, 19980517, Ｖ０ｌ．９５ Ｎｏ．６, ２８６２−２８６７, US, Ｔｈｅ Ｎａｔｉｏｎａｌ Ａｃａｄｅｍｙ ｏｆ Ｓｃｉｅｎｃｅｓ *

Also Published As

Publication number Publication date
WO2001055692A2 (en) 2001-08-02
AU2007201915A1 (en) 2007-05-24
CA2398358A1 (en) 2001-08-02
EP1254251A4 (en) 2004-07-21
AU3114201A (en) 2001-08-07
AU785364B2 (en) 2007-02-01
DE60129932D1 (de) 2007-09-27
ES2290111T3 (es) 2008-02-16
DE60129932T2 (de) 2008-06-19
ATE370416T1 (de) 2007-09-15
EP1254251A2 (en) 2002-11-06
EP1254251B1 (en) 2007-08-15
WO2001055692A3 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
Cervellati et al. Oxidative damage and the pathogenesis of menopause related disturbances and diseases
Palmer et al. Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease
Palmer et al. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease
Lee et al. Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide
Klatt et al. A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease
Lu et al. FDX1 enhances endometriosis cell cuproptosis via G6PD-mediated redox homeostasis
Völkel et al. Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease
Abe et al. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease
JP2009535425A (ja) 有機化合物の使用
Gezen-Ak et al. Molecular basis of vitamin D action in neurodegeneration: the story of a team perspective
Zoia et al. Fibroblast glutamate transport in aging and in AD: correlations with disease severity
Turk et al. Therapeutic strategies in adrenoleukodystrophy
Steinberg et al. A PEX10 defect in a patient with no detectable defect in peroxisome assembly or metabolism in cultured fibroblasts
Cascio et al. Pathways of dehydroepiandrosterone formation in rat brain glia
Tao et al. Phenylbutyrate modulates polyamine acetylase and ameliorates Snyder-Robinson syndrome in a Drosophila model and patient cells
Ashby et al. Altered expression of human mitochondrial branched chain aminotransferase in dementia with lewy bodies and vascular dementia
Lecanu et al. Identification of naturally occurring spirostenols preventing β-amyloid-induced neurotoxicity
AU2007201915A1 (en) Neurosteroids as markers for Alzheimer's disease
Varghese et al. Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population
Bičíková et al. Plasma levels of 7-hydroxylated dehydroepiandrosterone (DHEA) metabolites and selected amino-thiols as discriminatory tools of Alzheimer's disease and vascular dementia.
Gabilondo et al. Monoamine oxidase B activity is increased in human gliomas
Karkucinska-Wieckowska et al. Increased reactive oxygen species (ROS) production and low catalase level in fibroblasts of a girl with MEGDEL association (Leigh syndrome, deafness, 3-methylglutaconic aciduria)
Borowik et al. Senolytic treatment does not mitigate oxidative stress-induced muscle atrophy but improves muscle force generation in CuZn superoxide dismutase knockout mice
Banbury Stress biomarkers in the tear film
Calvo et al. Thyroid hormones in human tumoral and normal nervous tissues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100813

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101013

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110125